Standard BioTools Inc expected to post a loss of 7 cents a share - Earnings Preview

Standard BioTools

02/05/2025 22:39

Standard BioTools Inc LAB.OQ LAB.O is expected to show a fall in quarterly revenue when it reports  results on May 6 for the period ending March 31 2025

The South San Francisco California-based  company is expected to report a 11.9% decrease in revenue to $40.1 million from $45.54 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Standard BioTools Inc is for a loss of 7 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Standard BioTools Inc is $2.38​, above​ its last closing price of $1.11. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.06
-0.07
-0.09
Missed
-28.6
Sep. 30 2024
-0.09
-0.09
-0.07
Beat
22.2
Jun. 30 2024
-0.09
-0.08
-0.12
Missed
-41.2​
Mar. 31 2024
-0.13
-0.11
-0.27
Missed
-138.2
​​Dec. 31 2023
-0.13
-0.25
Missed
-92.3
Sep. 30 2023
-0.12
-0.12
-0.27
Missed
-125​
Jun. 30 2023
-0.21
-0.21
-0.22
Missed
-4.8

This summary was machine generated May 2 at 21:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)